Nathan D Wong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7709004/publications.pdf

Version: 2024-02-01

304 papers 48,682 citations

74 h-index

9264

217 g-index

339 all docs

339 docs citations

times ranked

339

47061 citing authors

#	Article	IF	CITATIONS
1	Heart Disease and Stroke Statistics—2014 Update. Circulation, 2014, 129, e28-e292.	1.6	4,522
2	Heart Disease and Stroke Statistics—2013 Update. Circulation, 2013, 127, e6-e245.	1.6	4,387
3	Heart Disease and Stroke Statistics—2011 Update. Circulation, 2011, 123, e18-e209.	1.6	4,379
4	Heart Disease and Stroke Statistics—2012 Update. Circulation, 2012, 125, e2-e220.	1.6	4,096
5	Heart Disease and Stroke Statistics—2010 Update. Circulation, 2010, 121, e46-e215.	1.6	4,053
6	Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups. New England Journal of Medicine, 2008, 358, 1336-1345.	27.0	2,498
7	Heart Disease and Stroke Statistics—2009 Update. Circulation, 2009, 119, e21-181.	1.6	2,039
8	Is Pulse Pressure Useful in Predicting Risk for Coronary Heart Disease?. Circulation, 1999, 100, 354-360.	1.6	1,602
9	Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults. Circulation, 2004, 110, 1245-1250.	1.6	1,549
10	Computed Tomographic Angiography Characteristics of Atherosclerotic Plaques Subsequently Resulting in Acute Coronary Syndrome. Journal of the American College of Cardiology, 2009, 54, 49-57.	2.8	1,255
11	Does the Relation of Blood Pressure to Coronary Heart Disease Risk Change With Aging?. Circulation, 2001, 103, 1245-1249.	1.6	1,173
12	Calcified Coronary Artery Plaque Measurement with Cardiac CT in Population-based Studies: Standardized Protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) Study. Radiology, 2005, 234, 35-43.	7.3	746
13	Predominance of Isolated Systolic Hypertension Among Middle-Aged and Elderly US Hypertensives. Hypertension, 2001, 37, 869-874.	2.7	624
14	Epidemiological studies of CHD and the evolution of preventive cardiology. Nature Reviews Cardiology, 2014, 11, 276-289.	13.7	486
15	Relationship between stress-induced myocardial ischemia and atherosclerosis measured by coronary calcium tomography. Journal of the American College of Cardiology, 2004, 44, 923-930.	2.8	416
16	Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events. American Journal of Cardiology, 2000, 86, 495-498.	1.6	404
17	Impact of Coronary Artery Calcium Scanning on Coronary Risk Factors and Downstream Testing. Journal of the American College of Cardiology, 2011, 57, 1622-1632.	2.8	390
18	Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). European Heart Journal, 2018, 39, 2401-2408.	2.2	383

#	Article	IF	CITATIONS
19	M-Mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the cardiovascular health) Tj ETQq1 1 0.78431	4 rg BT /Ov	veskorck 10 T
20	Epidemiology of Diabetes Mellitus and Cardiovascular Disease. Current Cardiology Reports, 2019, 21, 21.	2.9	363
21	Coronary Calcium Does Not Accurately Predict Near-Term Future Coronary Events in High-Risk Adults. Circulation, 1999, 99, 2633-2638.	1.6	344
22	Progression of Coronary Calcium and Incident Coronary Heart Disease Events. Journal of the American College of Cardiology, 2013, 61, 1231-1239.	2.8	341
23	Coronary Calcium Predicts Events Better With Absolute Calcium Scores Than Age-Sex-Race/Ethnicity Percentiles. Journal of the American College of Cardiology, 2009, 53, 345-352.	2.8	330
24	Position paper Statin intolerance $\hat{a}\in$ " an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Archives of Medical Science, 2015, 1, 1-23.	0.9	311
25	Coronary Artery Calcium Scores and Risk for Cardiovascular Events in Women Classified as "Low Risk―Based on Framingham Risk Score. Archives of Internal Medicine, 2007, 167, 2437.	3.8	307
26	Single Versus Combined Blood Pressure Components and Risk for Cardiovascular Disease. Circulation, 2009, 119, 243-250.	1.6	287
27	Coronary Calcium Measurements: Effect of CT Scanner Type and Calcium Measure on Rescan Reproducibility—MESA Study. Radiology, 2005, 236, 477-484.	7.3	264
28	The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes, 2006, 55, 3556-3565.	0.6	238
29	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutrition Reviews, 2017, 75, 731-767.	5.8	238
30	The metabolic syndrome, diabetes, and subclinicalatherosclerosis assessed by coronary calcium. Journal of the American College of Cardiology, 2003, 41, 1547-1553.	2.8	216
31	The Role of Nutraceuticals in StatinÂIntolerant Patients. Journal of the American College of Cardiology, 2018, 72, 96-118.	2.8	216
32	Pericardial Fat Burden on ECG-Gated Noncontrast CT in Asymptomatic Patients Who Subsequently Experience Adverse Cardiovascular Events. JACC: Cardiovascular Imaging, 2010, 3, 352-360.	5.3	210
33	Echocardiographic Design of a Multicenter Investigation of Free-living Elderly Subjects: The Cardiovascular Health Study. Journal of the American Society of Echocardiography, 1992, 5, 63-72.	2.8	209
34	Inadequate Control of Hypertension in US Adults With Cardiovascular Disease Comorbidities in 2003-2004. Archives of Internal Medicine, 2007, 167, 2431.	3.8	207
35	Coronary calcium and atherosclerosis by ultrafast computed tomography in asymptomatic men and women: Relation to age and risk factors. American Heart Journal, 1994, 127, 422-430.	2.7	206
36	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Archives of Medical Science, 2017, 5, 965-1005.	0.9	206

#	Article	IF	Citations
37	Impact of Subclinical Atherosclerosis on Cardiovascular Disease Events in Individuals With Metabolic Syndrome and Diabetes. Diabetes Care, 2011, 34, 2285-2290.	8.6	186
38	Family History of Premature Coronary Heart Disease and Coronary Artery Calcification. Circulation, 2007, 116, 619-626.	1.6	160
39	Hypertension and Cardiovascular Disease: Contributions of the Framingham Heart Study. Global Heart, 2013, 8, 49.	2.3	158
40	Thoracic aortic calcification and coronary heart disease events: The multi-ethnic study of atherosclerosis (MESA). Atherosclerosis, 2011, 215, 196-202.	0.8	156
41	Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004. American Heart Journal, 2008, 156, 112-119.	2.7	153
42	Cardiovascular Disease in U.S. Patients With Metabolic Syndrome, Diabetes, and Elevated C-Reactive Protein. Diabetes Care, 2005, 28, 690-693.	8.6	152
43	Coronary Artery Calcium Score for Long-term Risk Classification in Individuals With Type 2 Diabetes and Metabolic Syndrome From the Multi-Ethnic Study of Atherosclerosis. JAMA Cardiology, 2017, 2, 1332.	6.1	151
44	Prevalence of statin intolerance: a meta-analysis. European Heart Journal, 2022, 43, 3213-3223.	2.2	151
45	Epicardial adipose tissue density and volume are related to subclinical atherosclerosis, inflammation and major adverse cardiac events in asymptomatic subjects. Journal of Cardiovascular Computed Tomography, 2018, 12, 67-73.	1.3	143
46	Polymorphism of the Soluble Epoxide Hydrolase Is Associated With Coronary Artery Calcification in African-American Subjects. Circulation, 2004, 109, 335-339.	1.6	140
47	Detection of coronary calcification with electron-beam computed tomography: Evaluation of interexamination reproducibility and comparison of three image-acquisition protocols. American Heart Journal, 1996, 132, 550-558.	2.7	139
48	Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. American Journal of Cardiology, 2003, 91, 1421-1426.	1.6	139
49	Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors — Results from a systematic review and meta-analysis of randomized controlled trials. International Journal of Cardiology, 2015, 189, 47-55.	1.7	138
50	Metabolic Syndrome, Diabetes, and Incidence and Progression of Coronary Calcium. JACC: Cardiovascular Imaging, 2012, 5, 358-366.	5.3	137
51	Prevalence, Treatment, and Control of Combined Hypertension and Hypercholesterolemia in the United States. American Journal of Cardiology, 2006, 98, 204-208.	1.6	135
52	Clinical Outcomes After Both Coronary Calcium Scanning and Exercise Myocardial Perfusion Scintigraphy. Journal of the American College of Cardiology, 2007, 49, 1352-1361.	2.8	132
53	RISK FACTORS FOR LONG-TERM CORONARY PROGNOSIS AFTER INITIAL MYOCARDIAL INFARCTION: THE FRAMINGHAM STUDY. American Journal of Epidemiology, 1989, 130, 469-480.	3.4	130
54	Does coronary artery screening by electron beam computed tomography motivate potentially beneficial lifestyle behaviors?. American Journal of Cardiology, 1996, 78, 1220-1223.	1.6	129

#	Article	IF	CITATIONS
55	Molecular Imaging of Matrix Metalloproteinase in Atherosclerotic Lesions. Journal of the American College of Cardiology, 2008, 52, 1847-1857.	2.8	125
56	Prognostic significance of cardiac cinefluoroscopy for coronary calcific deposits in asymptomatic high risk subjects. Journal of the American College of Cardiology, 1994, 24, 354-358.	2.8	116
57	Metabolic Syndrome and Diabetes Are Associated With an Increased Likelihood of Inducible Myocardial Ischemia Among Patients With Subclinical Atherosclerosis. Diabetes Care, 2005, 28, 1445-1450.	8.6	111
58	Distribution of C-Reactive Protein and Its Relation to Risk Factors and Coronary Heart Disease Risk Estimation in the National Health and Nutrition Examination Survey (NHANES) III. Preventive Cardiology, 2001, 4, 109-114.	1.1	109
59	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project. European Journal of Preventive Cardiology, 2017, 24, 1637-1645.	1.8	109
60	Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Research and Clinical Practice, 2005, 70, 263-269.	2.8	106
61	Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study. Diabetes Care, 2016, 39, 668-676.	8.6	105
62	Improving the CAC Score by Addition of Regional Measures of Calcium Distribution. JACC: Cardiovascular Imaging, 2016, 9, 1407-1416.	5.3	101
63	Thoracic Aortic Calcium Versus Coronary Artery Calcium for the Prediction of Coronary Heart Disease and Cardiovascular Disease Events. JACC: Cardiovascular Imaging, 2009, 2, 319-326.	5.3	99
64	Left Ventricular Mass in the Elderly. Hypertension, 1997, 29, 1095-1103.	2.7	97
65	Abdominal Aortic Calcium, Coronary Artery Calcium, and Cardiovascular Morbidity and Mortality in the Multi-Ethnic Study of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1574-1579.	2.4	95
66	Insulin Resistance, Metabolic Syndrome, and Subclinical Atherosclerosis. Diabetes Care, 2007, 30, 2951-2956.	8.6	91
67	Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. American Journal of Preventive Cardiology, 2020, 1, 100009.	3.0	90
68	Racial differences in coronary calcium prevalence among high-risk adults. American Journal of Cardiology, 1995, 75, 1088-1091.	1.6	87
69	Measuring Coronary Calcium on CT Images Adjusted for Attenuation Differences. Radiology, 2005, 235, 403-414.	7.3	87
70	Does Low Diastolic Blood Pressure Contribute to the Risk of Recurrent Hypertensive Cardiovascular Disease Events?. Hypertension, 2015, 65, 299-305.	2.7	83
71	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Frontiers in Cardiovascular Medicine, 2020, 7, 88.	2.4	82
72	Coronary calcium and cardiovascular event risk: Evaluation by age- and sex-specific quartiles. American Heart Journal, 2002, 143, 456-459.	2.7	81

#	Article	IF	CITATIONS
73	Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Research and Clinical Practice, 2007, 77, 126-133.	2.8	78
74	Abdominal aortic calcium and multi-site atherosclerosis: The Multiethnic Study of Atherosclerosis. Atherosclerosis, 2011, 214, 436-441.	0.8	77
7 5	Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: Comparison by prevalent cardiovascular disease status. Diabetes and Vascular Disease Research, 2013, 10, 505-513.	2.0	77
76	Deep Learning–Based Quantification of Epicardial Adipose Tissue Volume and Attenuation Predicts Major Adverse Cardiovascular Events in Asymptomatic Subjects. Circulation: Cardiovascular Imaging, 2020, 13, e009829.	2.6	77
77	Prevention and Rehabilitation. American Heart Journal, 2003, 145, 888-895.	2.7	76
78	Relation of thoracic aortic and aortic valve calcium to coronary artery calcium and risk assessment. American Journal of Cardiology, 2003, 92, 951-955.	1.6	74
79	Ageâ€Related Trends in Cardiovascular Morbidity and Physical Functioning in the Elderly: The Cardiovascular Health Study. Journal of the American Geriatrics Society, 1993, 41, 1047-1056.	2.6	72
80	Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. Journal of Clinical Lipidology, 2016, 10, 1109-1118.	1.5	66
81	Detection of coronary artery calcium by ultrafast computed tomography and its relation to clinical evidence of coronary artery disease. American Journal of Cardiology, 1994, 73, 223-227.	1.6	63
82	Task force #4—how do we select patients for atherosclerosis imaging?. Journal of the American College of Cardiology, 2003, 41, 1898-1906.	2.8	61
83	Impact of C-Reactive Protein on the Likelihood of Peripheral Arterial Disease in United States Adults With the Metabolic Syndrome, Diabetes Mellitus, and Preexisting Cardiovascular Disease. American Journal of Cardiology, 2005, 96, 655-658.	1.6	61
84	Multisite extracoronary calcification indicates increased risk of coronary heart disease and all-cause mortality: The Multi-Ethnic Study of Atherosclerosis. Journal of Cardiovascular Computed Tomography, 2015, 9, 406-414.	1.3	61
85	Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis. Journal of Clinical Lipidology, 2017, 11, 1223-1233.	1.5	61
86	Development of a new diabetes risk prediction tool for incident coronary heart disease events: The Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. Atherosclerosis, 2014, 236, 411-417.	0.8	60
87	Global cardiovascular disease risk assessment in United States adults with diabetes. Diabetes and Vascular Disease Research, 2012, 9, 146-152.	2.0	59
88	Cardiovascular Risk Factor Control and Adherence to Recommended Lifestyle and Medical Therapies in Persons With Coronary Heart Disease (from the National Health and Nutrition Examination Survey) Tj ETQq0 0 () rg B ₹ /Ove	erlossk 10 Tf 50
89	The Association of Framingham and Reynolds Risk Scores With Incidence and Progression of Coronary Artery Calcification in MESA (Multi-Ethnic Study of Atherosclerosis). Journal of the American College of Cardiology, 2011, 58, 2076-2083.	2.8	58
90	Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. American Journal of Preventive Cardiology, 2022, 10, 100335.	3.0	58

#	Article	IF	CITATIONS
91	Comparative Value of Coronary Artery Calcium and Multiple Blood Biomarkers for Prognostication of Cardiovascular Events. American Journal of Cardiology, 2012, 109, 1449-1453.	1.6	57
92	Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. Journal of Clinical Lipidology, 2019, 13, 100-108.	1.5	56
93	Myeloperoxidase, Subclinical Atherosclerosis, and Cardiovascular Disease Events. JACC: Cardiovascular Imaging, 2009, 2, 1093-1099.	5.3	55
94	Concordance of Coronary Artery Calcium Estimates Between MDCT and Electron Beam Tomography. American Journal of Roentgenology, 2005, 185, 1542-1545.	2.2	54
95	Association Between Coronary Artery Calcification Progression and Microalbuminuria. JACC: Cardiovascular Imaging, 2010, 3, 595-604.	5.3	54
96	Blood pressure categories, hypertensive subtypes, and the metabolic syndrome. Journal of Hypertension, 2006, 24, 2009-2016.	0.5	53
97	Comparison of demographic factors and cardiovascular risk factor control among U.S. adults with type 2 diabetes by insulin treatment classification. Journal of Diabetes and Its Complications, 2012, 26, 169-174.	2.3	53
98	Gender and ethnic differences in the prevalence of type 2 diabetes among Asian subgroups in California. Journal of Diabetes and Its Complications, 2013, 27, 429-435.	2.3	53
99	The Metabolic Syndrome in East Asians. Journal of the Cardiometabolic Syndrome, 2007, 2, 276-282.	1.7	51
100	Metabolic Syndrome. American Journal of Cardiovascular Drugs, 2007, 7, 259-272.	2.2	50
101	Family history of coronary heart disease and the incidence and progression of coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis, 2014, 232, 369-376.	0.8	48
102	The relationship between Lp(a) and CVD outcomes: a systematic review. Lipids in Health and Disease, 2016, 15, 95.	3.0	47
103	Relation of coronary calcium progression and control of lipids according to National Cholesterol Education Program guidelines. American Journal of Cardiology, 2004, 94, 431-436.	1.6	46
104	Racial and Geographic Disparities in Internet Use in the U.S. Among Patients With Hypertension or Diabetes: Implications for Telehealth in the Era of COVID-19. Diabetes Care, 2021, 44, e15-e17.	8.6	46
105	Carotid Plaque Characterization, Stenosis, and Intima-Media Thickness According to Age and Gender in a Large Registry Cohort. American Journal of Cardiology, 2016, 117, 1185-1191.	1.6	45
106	Global Coronary Heart Disease Risk Assessment of Individuals With the Metabolic Syndrome in the U.S Diabetes Care, 2008, 31, 1405-1409.	8.6	44
107	Cumulative intake of artificially sweetened and sugar-sweetened beverages and risk of incident type 2 diabetes in young adults: the Coronary Artery Risk Development In Young Adults (CARDIA) Study. American Journal of Clinical Nutrition, 2019, 110, 733-741.	4.7	44
108	Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). American Journal of Cardiology, 2016, 117, 1921-1927.	1.6	43

#	Article	IF	Citations
109	Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007–2014. Diabetes Care, 2019, 42, 2307-2314.	8.6	43
110	Relation Between COPD Severity and Global Cardiovascular Risk in US Adults. Chest, 2012, 142, 1118-1125.	0.8	42
111	Coronary artery Calcium predicts Cardiovascular events in participants with a low lifetime risk of Cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis, 2016, 246, 367-373.	0.8	42
112	Control of Cardiovascular Risk Factors Among US Adults With Type 2 Diabetes With and Without Cardiovascular Disease. American Journal of Cardiology, 2019, 124, 522-527.	1.6	41
113	Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry. Diabetes, Obesity and Metabolism, 2019, 21, 1121-1127.	4.4	40
114	Knowledge Gaps, Challenges, and Opportunities in Health and Prevention Research for Asian Americans, Native Hawaiians, and Pacific Islanders: A Report From the 2021 National Institutes of Health Workshop. Annals of Internal Medicine, 2022, 175, 574-589.	3.9	40
115	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 2021, 67, 40-52.	3.1	39
116	Prevalence and Distribution of Sub-Clinical Atherosclerosis by Screening Vascular Ultrasound in Low and Intermediate Risk Adults: The New York Physicians Study. Journal of the American Society of Echocardiography, 2009, 22, 1145-1151.	2.8	37
117	Machine learning integration of circulating and imaging biomarkers for explainable patient-specific prediction of cardiac events: A prospective study. Atherosclerosis, 2021, 318, 76-82.	0.8	37
118	Effect of an Antimicrobial Agent on Atherosclerotic Plaques. Journal of the American College of Cardiology, 2010, 55, 1240-1249.	2.8	36
119	What Do Carotid Intima-Media Thickness and Plaque Add to the Prediction of Stroke and Cardiovascular Disease Risk in Older Adults? The Cardiovascular Health Study. Journal of the American Society of Echocardiography, 2014, 27, 998-1005.e2.	2.8	36
120	Cardiovascular comorbidities and blood pressure control in stroke survivors. Journal of Hypertension, 2009, 27, 1056-1063.	0.5	35
121	The significance of low DBP in US adults with isolated systolic hypertension. Journal of Hypertension, 2011, 29, 1101-1108.	0.5	35
122	Multisite atherosclerosis in subjects with metabolic syndrome and diabetes and relation to cardiovascular events: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2019, 282, 202-209.	0.8	35
123	Prevalence of US Adults with Triglycerides ≥ 150Âmg/dl: NHANES 2007–2014. Cardiology and Ther 2020, 9, 207-213.	rapy, 2.8,	35
124	Global Cardiovascular Risk Associated With Hypertension and Extent of Treatment and Control According to Risk Group. American Journal of Hypertension, 2012, 25, 561-567.	2.0	34
125	Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of realâ€world evidence. Diabetes, Obesity and Metabolism, 2020, 22, 279-289.	4.4	33
126	Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study. Cardiovascular Diabetology, 2021, 20, 27.	6.8	33

#	Article	IF	Citations
127	Legacy of the Framingham Heart Study: Rationale, Design, Initial Findings, and Implications. Global Heart, 2013, 8, 3.	2.3	32
128	Do Risk Factors Explain the Increased Prevalence of Type 2 Diabetes Among California Asian Adults?. Journal of Immigrant and Minority Health, 2011, 13, 803-808.	1.6	31
129	Residual dyslipidemia according to low-density lipoprotein cholesterol, non–high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010. Journal of Clinical Lipidology, 2015, 9, 525-532.	1.5	31
130	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). Nutrition Research Reviews, 2020, 33, 155-179.	4.1	31
131	Residual Dyslipidemia Among United States Adults Treated With Lipid Modifying Therapy (Data from) Tj ETQq 11 112, 373-379.	0.784314 1.6	1 rgBT /Overl 30
132	Preventable Coronary Heart Disease Events from Control of Cardiovascular Risk Factors in US Adults With Diabetes (Projections from Utilizing the UKPDS Risk Engine). American Journal of Cardiology, 2014, 113, 1356-1361.	1.6	30
133	Racial/ethnic differences in control of cardiovascular risk factors among type 2 diabetes patients in an insured, ambulatory care population. Journal of Diabetes and Its Complications, 2013, 27, 34-40.	2.3	29
134	Left Atrial Septal Pouch in Cryptogenic Stroke. Frontiers in Neurology, 2015, 6, 57.	2.4	29
135	Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry. Diabetes Care, 2016, 39, e99-e101.	8.6	29
136	Thoracic aortic calcium, cardiovascular disease events, and all-cause mortality in asymptomatic individuals with zero coronary calcium: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis, 2017, 257, 1-8.	0.8	29
137	The Multiethnic Study of Atherosclerosis. Global Heart, 2016, 11, 267.	2.3	29
138	The art of cardiovascular risk assessment. Clinical Cardiology, 2018, 41, 677-684.	1.8	28
139	Sex Differences in Coronary Artery Calcium and Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in Adults With Diabetes: The Coronary Calcium Consortium. Diabetes Care, 2020, 43, 2597-2606.	8.6	27
140	Relation of echocardiographic left ventricular mass, geometry and wall stress, and left atrial dimension to coronary calcium in young adults (the CARDIA study). American Journal of Cardiology, 2005, 95, 626-629.	1.6	26
141	LV Mass as a Predictor of CVD Events inÂOlder Adults With and Without Metabolic Syndrome and Diabetes. JACC: Cardiovascular Imaging, 2015, 8, 1007-1015.	5.3	26
142	Dietary patterns, plasma vitamins and Trans fatty acids are associated with peripheral artery disease. Lipids in Health and Disease, 2017, 16, 254.	3.0	26
143	Nonalcoholic Fatty Liver Disease Is Associated With Arterial Distensibility and Carotid Intima-Media Thickness: (from the Multi-Ethnic Study of Atherosclerosis). American Journal of Cardiology, 2019, 124, 534-538.	1.6	26
144	Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials. Frontiers in Cardiovascular Medicine, 2019, 6, 14.	2.4	26

#	Article	IF	CITATIONS
145	Association of FVC and Total Mortality in US Adults With Metabolic Syndrome and Diabetes. Chest, 2009, 136, 171-176.	0.8	25
146	N-terminal Pro B-type Natriuretic Peptide and High-sensitivity Cardiac Troponin as Markers for Heart Failure and Cardiovascular Disease Risks According to Glucose Status (from the Multi-Ethnic Study) Tj ETQq0 C	0 rgBa ∕Ov	erl oo k 10 Tf 5
147	Association of C-Reactive Protein With Reduced Forced Vital Capacity in a Nonsmoking U.S. Population With Metabolic Syndrome and Diabetes. Diabetes Care, 2008, 31, 2000-2002.	8.6	24
148	Extent of Control of Cardiovascular Risk Factors and Adherence to Recommended Therapies in US Multiethnic Adults with Coronary Heart Disease. American Journal of Cardiovascular Drugs, 2010, 10, 109-114.	2.2	24
149	Risk Factors for the Development and Progression of Thoracic Aorta Calcification. Academic Radiology, 2015, 22, 1536-1545.	2.5	23
150	Breast Arterial Calcification: a Novel Cardiovascular Risk Enhancer Among Postmenopausal Women. Circulation: Cardiovascular Imaging, 2022, 15, e013526.	2.6	23
151	Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry <code>[®].</code> Journal of the American Heart Association, 2017, 6, .	3.7	21
152	Neck Circumference Is Not Associated With Subclinical Atherosclerosis in Retired National Football League Players. Clinical Cardiology, 2014, 37, 402-407.	1.8	20
153	A US Claims-Based Analysis of Real-World Lipid-Lowering Treatment Patterns in Patients With High Cardiovascular Disease Risk or a Previous Coronary Event. American Journal of Cardiology, 2016, 117, 495-500.	1.6	20
154	Thoracic extra-coronary calcification for the prediction of stroke: TheÂMulti-Ethnic Study of Atherosclerosis. Atherosclerosis, 2017, 267, 61-67.	0.8	20
155	Association of lung function and chronic obstructive pulmonary disease with American Heart Association's Life's Simple 7 cardiovascular health metrics. Respiratory Medicine, 2017, 131, 85-93.	2.9	20
156	Cardiovascular Disease, Mortality Risk, and Healthcare Costs by Lipoprotein(a) Levels According to Lowâ€density Lipoprotein Cholesterol Levels in Older Highâ€risk Adults. Clinical Cardiology, 2016, 39, 413-420.	1.8	19
157	Progression of Coronary Artery Calcium and Incident Heart Failure: The Multiâ€Ethnic Study of Atherosclerosis. Journal of the American Heart Association, 2017, 6, .	3.7	19
158	Predicting Long-Term Absence of Coronary Artery Calcium in Metabolic Syndrome and Diabetes. JACC: Cardiovascular Imaging, 2021, 14, 219-229.	5. 3	19
159	Combined Association of Lipids and Blood Pressure in Relation to Incident Cardiovascular Disease in the Elderly: The Cardiovascular Health Study. American Journal of Hypertension, 2010, 23, 161-167.	2.0	18
160	Use of coronary artery calcium testing to improve coronary heart disease risk assessment in a lung cancer screening population: The Multi-Ethnic Study of Atherosclerosis (MESA). Journal of Cardiovascular Computed Tomography, 2018, 12, 493-499.	1.3	17
161	Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States. American Journal of Preventive Cardiology, 2020, 1, 100010.	3.0	17
162	Parental history of stroke and myocardial infarction predicts coronary artery calcification: The Coronary Artery Risk Development in Young Adults (CARDIA) study. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 421-426.	2.8	17

#	Article	IF	CITATIONS
163	Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: A 2019 update. American Journal of Preventive Cardiology, 2022, 10, 100336.	3.0	17
164	Coronary Heart Disease Events Preventable by Control of Blood Pressure and Lipids in US Adults With Hypertension. Journal of Clinical Hypertension, 2007, 9, 436-443.	2.0	16
165	Density of calcium in the ascending thoracic aorta and risk of incident cardiovascular disease events. Atherosclerosis, 2017, 265, 190-196.	0.8	16
166	Incidence of diabetes according to metabolically healthy or unhealthy normal weight or overweight/obesity in postmenopausal women: the Women's Health Initiative. Menopause, 2020, 27, 640-647.	2.0	16
167	Association of Body Mass Index and Waist Circumference with Subclinical Atherosclerosis in Retired NFL Players. Southern Medical Journal, 2014, 107, 633-639.	0.7	16
168	Identification by Ultrasound Evaluation of the Carotid and Femoral Arteries of High-Risk Subjects Missed by Three Validated Cardiovascular Disease Risk Algorithms. American Journal of Cardiology, 2015, 116, 1617-1623.	1.6	15
169	Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond. Cardiovascular Diagnosis and Therapy, 2017, 67, S11-S20.	1.7	15
170	Angina in Coronary Artery Disease Patients With and Without Diabetes: ⟨scp⟩US⟨/scp⟩ National Health and Nutrition Examination Survey 2001–2010. Clinical Cardiology, 2016, 39, 30-36.	1.8	14
171	Progression of calcium density in the ascending thoracic aorta is inversely associated with incident cardiovascular disease events. European Heart Journal Cardiovascular Imaging, 2018, 19, 1343-1350.	1.2	14
172	The Importance and Role of Multiple Risk Factor Control in Type 2 Diabetes. Current Cardiology Reports, 2019, 21, 35.	2.9	14
173	Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 549-556.	3.0	14
174	PERSPECTIVES ? CME. Intensified Screening and Treatment of the Metabolic Syndrome for Cardiovascular Risk Reduction. Preventive Cardiology, 2005, 8, 47-54.	1.1	13
175	Prognostic Accuracy of B-Natriuretic Peptide Measurements and Coronary Artery Calcium in Asymptomatic Subjects (from the Early Identification of Subclinical Atherosclerosis by Noninvasive) Tj ETQq1 1	0.78.4314	rgBīī3/Overlo
176	Pulse Pressure. Journal of the American College of Cardiology, 2016, 67, 404-406.	2.8	13
177	Current guidelines on prevention with a focus on dyslipidemias. Cardiovascular Diagnosis and Therapy, 2017, 67, S4-S10.	1.7	13
178	Cardiovascular risk assessment: The foundation of preventive cardiology. American Journal of Preventive Cardiology, 2020, 1, 100008.	3.0	13
179	Evidence for Coronary Artery Calcification Screening in the Early Detection of Coronary Artery Disease and Implications of Screening in Developing Countries. Global Heart, 2014, 9, 399.	2.3	13
180	Relation of First and Total Recurrent Atherosclerotic Cardiovascular Disease Events to Increased Lipoprotein(a) Levels Among Statin Treated Adults With Cardiovascular Disease. American Journal of Cardiology, 2021, 145, 12-17.	1.6	13

#	Article	IF	Citations
181	Cardiovascular risk evaluation. Journal of Hypertension, 2002, 20, 2127-2130.	0.5	12
182	Karma of Cardiovascular Disease Risk Factors for Prevention and Management of Major Cardiovascular Events in the Context of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Frontiers in Cardiovascular Medicine, 2019, 6, 79.	2.4	12
183	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. Trends in Cardiovascular Medicine, 2021, 31, 49-56.	4.9	12
184	How Important Is Pulse Pressure as a Predictor of Cardiovascular Risk?. Hypertension, 2002, 39, .	2.7	11
185	Stratifying cardiovascular risk in diabetes: The role of diabetes-related clinical characteristics and imaging. Journal of Diabetes and Its Complications, 2016, 30, 1408-1415.	2.3	11
186	Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease. Journal of Diabetes and Its Complications, 2021, 35, 107767.	2.3	11
187	The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. Journal of Clinical Lipidology, 2019, 13, 754-761.	1.5	10
188	Utility of novel serum biomarkers to predict subclinical atherosclerosis: A sub-analysis of the EISNER study. Atherosclerosis, 2019, 282, 80-84.	0.8	10
189	REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National) Tj ETQq1	1 0.78431 <i>4</i>	1 rgBT /Overlo
190	Prevalence and Sociobehavioral Correlates of Tobacco Use Among Hispanic Children: The Tobacco Resistance Activity Program. Journal of School Health, 1993, 63, 391-396.	1.6	9
191	Role of coronary artery calcium in cardiovascular risk assessment. Expert Review of Cardiovascular Therapy, 2014, 12, 87-94.	1.5	9
192	Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol. American Journal of Cardiovascular Drugs, 2020, 20, 1-9.	2.2	9
193	Association of Coronary Calcium, Carotid Wall Thickness, and Carotid Plaque Progression With Low-Density Lipoprotein and High-Density Lipoprotein Particle Concentration Measured by Ion Mobility (From Multiethnic Study of Atherosclerosis [MESA]). American Journal of Cardiology, 2021, 142, 52-58.	1.6	9
194	Family History Fails to Detect the Majority of Children with High Capillary Blood Total Cholesterol. Journal of School Health, 1991, 61, 75-80.	1.6	8
195	Screening and risk stratification of patients with the metabolic syndrome and diabetes. Expert Review of Cardiovascular Therapy, 2006, 4, 181-190.	1.5	8
196	Coronary Artery Calcification and Coronary Atherosclerotic Disease. Cardiology Clinics, 2012, 30, 19-47.	2,2	8
197	Coronary Artery Calcium Screening in Persons with Metabolic Syndrome and Diabetes: Implications for Prevention. Metabolic Syndrome and Related Disorders, 2013, 11, 143-148.	1.3	8
198	Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. Atherosclerosis, 2014, 236, 251-256.	0.8	8

#	Article	IF	CITATIONS
199	Trends in Blood Pressure and High-Sensitivity Cardiac Troponin-T With Cardiovascular Disease: The Cardiovascular Health Study. American Journal of Hypertension, 2019, 32, 1013-1020.	2.0	8
200	The costs outweigh the benefits: seeing side-effects online may decrease adherence to statins. BMC Medical Informatics and Decision Making, 2020, 20, 197.	3.0	8
201	Cardiovascular and cardiometabolic prevention: high-level priority in the era of COVID-19. Cardiovascular Endocrinology and Metabolism, 2020, 9, 125-127.	1.1	8
202	A treatment-based algorithm for identification of diabetes type in the National Health and Nutrition Examination Survey. Cardiovascular Endocrinology and Metabolism, 2020, 9, 9-16.	1.1	8
203	Identification and Predictors for Cardiovascular Disease Risk Equivalents Among Adults With Diabetes. Diabetes Care, 2021, 44, 2411-2418.	8.6	8
204	Awareness, diagnosis and treatment of heterozygous familial hypercholesterolemia (HeFH) – Results of a US national survey. Journal of Clinical Lipidology, 2021, 15, 682-689.	1.5	8
205	Mustard oil and cardiovascular health: Why the controversy?. Journal of Clinical Lipidology, 2022, 16, 13-22.	1.5	8
206	Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of India. Journal of Clinical Lipidology, 2022, 16, 261-271.	1.5	8
207	Parental history of stroke and myocardial infarction predicts coronary artery calcification: The Coronary Artery Risk Development in Young Adults (CARDIA) study. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 421-426.	2.8	7
208	Comparison of Atherosclerotic Calcification Burden in Persons With the Cardiometabolic Syndrome and Diabetes. Journal of the Cardiometabolic Syndrome, 2006, 1, 90-94.	1.7	7
209	Cardiovascular Disease Risk Assessment: Review of Established and Newer Modalities. Current Treatment Options in Cardiovascular Medicine, 2015, 17, 57.	0.9	7
210	Reducing the Burden of Hypertension. JAMA Internal Medicine, 2016, 176, 532.	5.1	7
211	Peripheral Artery Disease and Aortic Disease. Global Heart, 2016, 11, 313.	2.3	7
212	Five-Year Residual Atherosclerotic Cardiovascular Disease Risk Prediction Model for Statin Treated Patients With Known Cardiovascular Disease. American Journal of Cardiology, 2020, 137, 7-11.	1.6	7
213	Development of a Risk Score for Atrial Fibrillation in Adults With Diabetes Mellitus (from the) Tj ETQq1 1 0.78431	4 rgBT /O	verlock 10 T
214	Metabolically Healthy/Unhealthy Overweight/Obesity Associations With Incident Heart Failure in Postmenopausal Women. Circulation: Heart Failure, 2021, 14, e007297.	3.9	7
215	Intermittent Nonhabitual Coffee Consumption and Risk of Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis. Journal of Atrial Fibrillation, 2019, 12, 2205.	0.5	7
216	Estimated prevalence of uncontrolled hypertension and multiple cardiovascular risk factors and their associated risk of coronary heart disease in the United States. Journal of the American Society of Hypertension, 2008, 2, 44-53.	2.3	6

#	Article	IF	Citations
217	Basic Science. Journal of the American Society of Hypertension, 2014, 8, 760-763.	2.3	6
218	Integrating Biomarkers and Imaging for Cardiovascular Disease Risk Assessment in Diabetes. Current Cardiology Reports, 2016, 18, 105.	2.9	6
219	Impact of lungâ€function measures on cardiovascular disease events in older adults with metabolic syndrome and diabetes. Clinical Cardiology, 2018, 41, 959-965.	1.8	6
220	Cumulative average dietary pattern scores in young adulthood and risk of incident type 2 diabetes: the CARDIA study. Diabetologia, 2019, 62, 2233-2244.	6.3	6
221	Assessment of the high risk and unmet need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource utilization, cost and burden of illness in the Diabetes Collaborative Registry. Endocrinology, Diabetes and Metabolism, 2020, 3, e00133.	2.4	6
222	Perceptions and Barriers on the Use of Proprotein Subtilisin/Kexin Type 9 Inhibitors in Heterozygous Familial Hypercholesterolemia (From a Survey of Primary Care Physicians and Cardiologists). American Journal of Cardiology, 2021, 152, 57-62.	1.6	6
223	Prevalence of United States adults with triglycerides ≥ 135 mg/dL: NHANES 2007–2014. Cardiology Journal, 2019, 26, 604-606.	1.2	6
224	Association of inflammatory markers and lipoprotein particle subclasses with progression of coronary artery calcium: The multi-ethnic study of atherosclerosis. Atherosclerosis, 2021, 339, 27-34.	0.8	6
225	Surrogate measures of atherosclerosis and implications for evaluating cardiovascular risk. Diabetes, Obesity and Metabolism, 2003, 5, 73-80.	4.4	5
226	Diagnosis of Coronary Artery Disease in Persons with Diabetes Mellitus. Current Diabetes Reports, 2012, 12, 286-293.	4.2	5
227	Examining Risk Factor Goal Attainment and Adherence to Treatment Among US Heart Failure Patients: The National Health and Nutrition Examination Survey 2007–2010. American Journal of Cardiovascular Drugs, 2014, 14, 41-49.	2.2	5
228	Risk factor indicators in offspring of patients with premature coronary heart disease in Banja Luka region/Republic of Srpska/Bosnia and Herzegovina. Archives of Medical Science, 2016, 4, 736-741.	0.9	5
229	The U.S. Prevention of Cardiovascular Disease Guidelines and Implications for Implementation in LMIC. Global Heart, 2020, 9, 445.	2.3	5
230	Cascade Screening and Treatment Initiation in Young Adults with Heterozygous Familial Hypercholesterolemia. Journal of Clinical Medicine, 2021, 10, 3090.	2.4	5
231	Prognostic value of serum soluble ST2 in stable coronary artery disease: a prospective observational study. Scientific Reports, 2021, 11, 15203.	3.3	5
232	Review: Cardiovascular risk assessment in the metabolic syndrome, screening for subclinical disease, and implications for treatment. British Journal of Diabetes and Vascular Disease, 2005, 5, 305-313.	0.6	4
233	The metabolic syndrome and dyslipidemia in primary and secondary prevention: examining the implications of recent trials. Clinical Lipidology, 2012, 7, 223-239.	0.4	4
234	The American Society for Preventive Cardiology: Our 30â€year legacy. Clinical Cardiology, 2016, 39, 627-630.	1.8	4

#	Article	IF	CITATIONS
235	Identifying the Very-High-Risk Atherosclerotic Cardiovascular DiseaseÂPatient. Journal of the American College of Cardiology, 2019, 74, 2508-2510.	2.8	4
236	Usefulness of a Coronary Artery Disease Predictive Algorithm to Predict Global Risk for Cardiovascular Disease and Acute Coronary Syndrome. American Journal of Cardiology, 2019, 123, 769-775.	1.6	4
237	Pre-diabetes, diabetes and predictors of incident angina among older women and men in the Cardiovascular Health Study. Diabetes and Vascular Disease Research, 2020, 17, 147916411988847.	2.0	4
238	Subclinical atherosclerosis in northern and southern China: the Chinese paradox. Journal of Geriatric Cardiology, $2011, 8, 72-77$.	0.2	4
239	Temporal changes in risk of cardiovascular events in people with newly diagnosed type 2 diabetes with and without cardiovascular disease. Journal of Diabetes and Its Complications, 2022, 36, 108126.	2.3	4
240	Apolipoprotein B as a Predictor of CVD. Journal of the Association of Physicians of India, The, 2020, 68, 50-53.	0.0	4
241	The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl. American Journal of Preventive Cardiology, 2022, 10, 100345.	3.0	4
242	Epidemiology of Hypertension. , 2005, , 16-28.		3
243	Evidence for Psychosocial Risk Factors and Behavioral Interventions in Cardiovascular Disease. Current Cardiovascular Risk Reports, 2012, 6, 528-533.	2.0	3
	Residual Risk After Treatment of Patients With Atherosclerotic Cardiovascular Disease With		
244	Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further) Tj ETQq0 0 0 rgBT	Oyerlock	10 Tf 50 38
244	Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further) Tj ETQq0 0 0 rgBT American Journal of Cardiology, 2017, 120, 1220-1222. The emergence of cardiodiabetology. Cardiovascular Endocrinology, 2017, 6, 3-7.	O.8	3 Tf 50 38
	Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further) Tj ETQq0 0 0 rgBT American Journal of Cardiology, 2017, 120, 1220-1222.	1.0	
245	Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further) Tj ETQq0 0 0 rgBT American Journal of Cardiology, 2017, 120, 1220-1222. The emergence of cardiodiabetology. Cardiovascular Endocrinology, 2017, 6, 3-7. Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes	0.8	3
245 246	Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further) Tj ETQq0 0 0 rgBT American Journal of Cardiology, 2017, 120, 1220-1222. The emergence of cardiodiabetology. Cardiovascular Endocrinology, 2017, 6, 3-7. Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). Journal of Diabetes and Its Complications, 2018, 32, 1035-1039. Post-trauma cardiovascular risk factors and subclinical atherosclerosis in young adults following	0.8	3
245 246 247	Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further) Tj ETQq0 0 0 rgBT American Journal of Cardiology, 2017, 120, 1220-1222. The emergence of cardiodiabetology. Cardiovascular Endocrinology, 2017, 6, 3-7. Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). Journal of Diabetes and Its Complications, 2018, 32, 1035-1039. Post-trauma cardiovascular risk factors and subclinical atherosclerosis in young adults following the war in Bosnia and Herzegovina. H¶gre Utbildning, 2019, 10, 1601988. Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey. Diabetes and	0.8 2.3 3.0	3 3
245 246 247 248	Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further) Tj ETQq0 0 0 rgBT American Journal of Cardiology, 2017, 120, 1220-1222. The emergence of cardiodiabetology. Cardiovascular Endocrinology, 2017, 6, 3-7. Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). Journal of Diabetes and Its Complications, 2018, 32, 1035-1039. Post-trauma cardiovascular risk factors and subclinical atherosclerosis in young adults following the war in Bosnia and Herzegovina. H¶gre Utbildning, 2019, 10, 1601988. Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey. Diabetes and Vascular Disease Research, 2020, 17, 147916412094567. Regional differences in the management of cardiovascular risk factors among adults with diabetes: An evaluation of the Diabetes Collaborative Registry. Journal of Diabetes and Its Complications, 2020,	0.8 2.3 3.0 2.0	3 3 3
245 246 247 248	Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further) Tj ETQq0 0 0 rgBT American Journal of Cardiology, 2017, 120, 1220-1222. The emergence of cardiodiabetology. Cardiovascular Endocrinology, 2017, 6, 3-7. Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). Journal of Diabetes and Its Complications, 2018, 32, 1035-1039. Post-trauma cardiovascular risk factors and subclinical atherosclerosis in young adults following the war in Bosnia and Herzegovina. HĀfgre Utbildning, 2019, 10, 1601988. Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey. Diabetes and Vascular Disease Research, 2020, 17, 147916412094567. Regional differences in the management of cardiovascular risk factors among adults with diabetes: An evaluation of the Diabetes Collaborative Registry. Journal of Diabetes and Its Complications, 2020, 34, 107591. Triglycerides and Atherosclerotic Cardiovascular Disease. Journal of the Association of Physicians of	0.8 2.3 3.0 2.0	3 3 3

#	Article	IF	Citations
253	Is There More to the Calcium Scan Than Just Coronary Calcium? â^—. JACC: Cardiovascular Imaging, 2016, 9, 1186-1187.	5.3	2
254	Hypertension Control in Africa: A Call to Action. Global Heart, 2019, 13, 1.	2.3	2
255	Preventive cardiology or cardiometabolic medicine: a new and emerging subspecialty?. Cardiovascular Endocrinology and Metabolism, 2020, 9, 66-69.	1.1	2
256	Sociodemographic and metabolic risk characteristics associated with metabolic weight categories in the Women's Health Initiative. Cardiovascular Endocrinology and Metabolism, 2020, 9, 42-48.	1.1	2
257	LEADER Trial Eligibility and Preventable Cardiovascular Events in US Adults with Diabetes: the National Health and Nutrition Examination Surveys 2007–2016. Cardiovascular Drugs and Therapy, 2020, 34, 737-743.	2.6	2
258	Evaluating Multisite Atherosclerosis and its Progression. Journal of the American College of Cardiology, 2020, 75, 1628-1630.	2.8	2
259	Assessment of The High risk and unmEt Need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource use, cost, and burden of illness in a commercially insured population. Journal of Diabetes and Its Complications, 2021, 35, 107859.	2.3	2
260	Should adults with type 2 diabetes be screened for atherosclerotic cardiovascular disease?. F1000Research, 2015, 4, 1167.	1.6	2
261	Implementation of secondary prevention methodologies in ischemic heart disease. Scripta Medica, 2010, 41, 29-35.	0.1	2
262	The Metabolic Syndrome and Preventive Cardiology: Working Together to Reduce Cardiometabolic Risks. Metabolic Syndrome and Related Disorders, 2006, 4, 233-236.	1.3	1
263	Combination of Lipid-Lowering Agents with Antihypertensive Drugs: A Joint Fight Against the Two Most Important Risk Factors?., 2015, , 153-163.		1
264	The Evolving Cardiovascular Disease Risk Scores for Persons with Diabetes Mellitus. Current Cardiology Reports, 2018, 20, 126.	2.9	1
265	Can Interventions on Socioeconomic Status Improve Cardiovascular Health? Role for American Heart Association's Life Simple 7. Global Heart, 2020, 14, 251.	2.3	1
266	Use of non‣DL lipidâ€lowering medications in patients with type 2 diabetes. Endocrinology, Diabetes and Metabolism, 2020, 3, e00126.	2.4	1
267	Response to the letter to the editor by Silverman-Lloyd etÂal. entitled: "Race is not a risk factor: Reframing discourse on racial health inequities in CVD prevention― American Journal of Preventive Cardiology, 2021, 6, 100188.	3.0	1
268	When is it Appropriate to Lower Low Density Lipoprotein-Cholesterol Levels to <30 mg/dL?. American Journal of Cardiology, 2021, 157, 142-144.	1.6	1
269	Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2021, 19, .	1.7	1
270	Lipid Association of India Expert Consensus Statement on Management of Dyslipidemia in Indians 2020: Part III. Journal of the Association of Physicians of India, The, 2020, 68, 8-9.	0.0	1

#	Article	IF	CITATIONS
271	Lifestyle Modification in the Prevention of Atherosclerotic Cardiovascular Disease. Journal of the Association of Physicians of India, The, 2020, 68, 10-20.	0.0	1
272	High Sensitivity C-Reactive Protein. Journal of the Association of Physicians of India, The, 2020, 68, 47-49.	0.0	1
273	Acute coronary syndromes in diabetes: Biomarkers of endothelial injury improve risk stratification and help identify predictors of risk. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102476.	3.6	1
274	Relation of Progression of Coronary Artery Calcium to Dementia (from the Multi-Ethnic Study of) Tj ETQq0 0 0 rg	gBT /Overl	ock 10 Tf 50
275	Equity and Prevention of Cardiovascular Diseases in Latin America and the Caribbean. Global Heart, 2022, 17, .	2.3	1
276	Should We Focus on Novel Risk Markers and Screening Tests to Better Predict and Prevent Cardiovascular Disease? Or Are We Putting the Cart Before the Horse?. Preventive Cardiology, 2010, 13, 149-151.	1.1	0
277	Racial Differences in the Ability of Subclinical Atherosclerosis Testing to Predict CVD. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	0
278	Editorial. Cardiovascular Endocrinology, 2017, 6, 44-44.	0.8	0
279	Cardiodiabetology: The convergence of diabetes and cardiovascular disease. Cardiovascular Endocrinology, 2017, 6, 2-2.	0.8	0
280	Cardiovascular Health Awareness and Promotion in Women: AHA's Life's Simple 7â,,¢ and Go Red for Womenâ,,¢. Current Cardiovascular Risk Reports, 2017, 11, 1.	2.0	0
281	Re: The art of cardiovascular risk assessment. Clinical Cardiology 2018;41(5):677-684 Clinical Cardiology, 2018, 41, 1111-1111.	1.8	0
282	Coronary Calcium in Type 1 Diabetes. JACC: Cardiovascular Imaging, 2019, 12, 1350-1352.	5. 3	0
283	Editors' Page. American Journal of Preventive Cardiology, 2020, 3, 100092.	3.0	0
284	The American journal of preventive cardiology: On a mission to help define a specialty. American Journal of Preventive Cardiology, 2020, 1, 100014.	3.0	0
285	Cover Image, Volume 22, Issue 3. Diabetes, Obesity and Metabolism, 2020, 22, .	4.4	0
286	Sex Differences in Diabetes, Heart Disease, and Beyond. Global Heart, 2020, 8, 113.	2.3	0
287	Editors' page - March 2021 issue. American Journal of Preventive Cardiology, 2021, 5, 100162.	3.0	0
288	Importance of applying treatment data to ascertain type 1 diabetes cases in health registries. BMJ Open Diabetes Research and Care, 2021, 9, e002280.	2.8	0

#	Article	IF	CITATIONS
289	Novel biomarker panel measuring endothelial injury identifies patients at risk of coronary artery syndrome and discordance with low-density lipoprotein cholesterol. Coronary Artery Disease, 2021, Publish Ahead of Print, e51-e58.	0.7	0
290	Editor's Message. American Journal of Preventive Cardiology, 2021, 6, 100191.	3.0	0
291	Editors' page for Sept 2021 issue. American Journal of Preventive Cardiology, 2021, 7, 100228.	3.0	0
292	Association of cardiovascular health with mortality among COPD patients: National Health and Nutrition Examination Survey III. Respiratory Medicine and Research, 2021, 80, 100860.	0.6	0
293	Highâ€impact Stepâ€aerobic and Progressive Strength Training on Bone Mineral Density in Sedentary Young Women. FASEB Journal, 2006, 20, LB27.	0.5	O
294	Cardiac Imaging for Ischemia in Asymptomatic Patients: Use of Coronary Artery Calcium Scanning to Improve Patient Selection: Lessons from the EISNER Study., 2011,, 411-427.		0
295	Evidence based cardiovascular risk assessment: Role of global risk scoring, biomarkers and subclinical disease evaluation. Srce I Krvni Sudovi, 2013, 32, 184-191.	0.1	0
296	Abstract 14373: Treatment Trends Among High Cardiovascular Disease Risk Patients Treated With Lipid-lowering Therapies: A United States Real-world Study. Circulation, 2015, 132, .	1.6	0
297	Cardiodiabetology: Reducing Risks to Optimize Cardiovascular Disease Outcomes. Contemporary Cardiology, 2021, , 227-248.	0.1	0
298	Editors' page. American Journal of Preventive Cardiology, 2021, 8, 100297.	3.0	0
299	Editors' Page – March 2022. American Journal of Preventive Cardiology, 2022, 9, 100320.	3.0	0
300	Low Density Lipoprotein Cholesterol Targets in Secondary Prevention of Atherosclerotic Cardiovascular Disease. Journal of the Association of Physicians of India, The, 2020, 68, 21-34.	0.0	0
301	Lipoprotein(a) and ASCVD risk. Journal of the Association of Physicians of India, The, 2020, 68, 42-46.	0.0	0
302	Non-HDL Cholesterol and Atherosclerotic Cardiovascular Disease. Journal of the Association of Physicians of India, The, 2020, 68, 54-58.	0.0	0
303	Detecting Coronary Calcium in YoungÂAdults. Journal of the American College of Cardiology, 2022, 79, 1887-1889.	2.8	0
304	Editors' Message June 2022. American Journal of Preventive Cardiology, 2022, , 100351.	3.0	0